CD8A and neoplasm: In brief, MEKi and CD40 Ab had clear cut synergistic actions in increasing the CD8+/regulatory T cell and M1/M2 macrophage ratios, suppressing the tumor growth-related gene signature and enhancing the pro-immunogenic signature, while such indications for drug synergy were lacking in the GEM/CD40 Ab combination.